This is the authors' abstract. We don't add key points for this paper.
Acute myeloid leukaemia (AML) is one of the most common malignancies seen to occur in human populations exposed to ionising radiation. 1 Mouse models have been widely used for quantitative and mechanistic studies of radiation leukaemogenesis; further, there is a similarity in the histopathological changes found in human AML and mouse AML. The majority of mouse radiation-induced AMLs (rAMLs) carry deletions of chromosome 2, and the Sfpi1/PU.1 haematopoietic transcription factor is located within the commonly deleted chromosome 2 region. 2 In most rAMLs and rAML cell lines (70%), Sfpi1/PU.1 suffers hemizygous loss accompanied by point mutations in the region encoding the ETS DNA-binding domain, leading to base substitutions at the R235 residue of the protein. 2 , 3 , 4 Sfpi1/PU.1 mutations have been identified in human AML, but these are rare; in contrast, the most common mutations in human AML involve the Flt3 receptor tyrosine kinase. Most of these mutations are internal tandem duplication ( Flt3- ITD) of 3–400 bp 5 that result in ligand-dependent dimerisation and receptor phosphorylation. The presence of a Flt3 -ITD appears to confer a more severe phenotype and a poor prognosis for AML sufferers. The majority of the remaining non-ITD mutations in Flt3 occur in the second tyrosine kinase domain, being mostly point mutations within codon 835 or the deletion of 836. 6
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Finnon et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: